Neuronal ceroid lipofuscinosis

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC

Neuronal ceroid lipofuscinosis
Synonyms	Batten disease, CLN disease
Pronounce	N/A
Specialty	N/A
Symptoms	Seizures, vision loss, cognitive decline, motor dysfunction
Complications	N/A
Onset	Childhood, but can vary depending on the type
Duration	Progressive
Types	N/A
Causes	Genetic mutation
Risks	Family history
Diagnosis	Genetic testing, MRI, EEG, skin biopsy
Differential diagnosis	Other neurodegenerative disorders
Prevention	N/A
Treatment	Symptomatic management, gene therapy (experimental)
Medication	N/A
Prognosis	Poor, progressive neurodegeneration
Frequency	Rare, varies by type
Deaths	N/A

Structure of Mannose-6-phosphate

Chemical structure of Flupirtine

Neuronal ceroid lipofuscinosis (NCL) is a group of autosomal recessive neurodegenerative disorders, which are collectively classified under the broader category of lysosomal storage disease. The NCLs are characterized by the accumulation of a specific type of lipid-protein complex, known as lipofuscin, within the cells of the body, particularly the neurons.

Etiology

The NCLs are caused by mutations in various genes, which lead to the production of defective proteins. These proteins are involved in the normal functioning of the lysosome, a cellular organelle responsible for the breakdown and recycling of cellular waste products. The defective proteins result in the accumulation of lipofuscin within the lysosomes, leading to cell death and the clinical manifestations of the disease.

Clinical Features

The clinical features of the NCLs vary depending on the specific type of NCL, but generally include progressive neurological deterioration, seizures, visual impairment, and motor dysfunction. The onset of symptoms can occur at any age, from infancy to adulthood.

Diagnosis

The diagnosis of NCL is based on the clinical features, genetic testing, and the presence of characteristic autofluorescent lipofuscin deposits in tissue samples.

Treatment

There is currently no cure for the NCLs. Treatment is supportive and aimed at managing the symptoms of the disease.

Prognosis

The prognosis for individuals with NCL is generally poor, with most individuals dying within a few years of diagnosis.

See Also

• Batten disease
• Lysosomal storage disease
• Neurodegenerative disorder

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia